Abstract
Retigabine is a new anticonvulsant in clinical development, which activates neuronal M-current by opening voltage-gated potassium channels (KCNQ2/3 and KCNQ3/5). Retigabine had demonstrated potent anticonvulsant activity in various animal models of epileptic seizures including partial and generalized seizure models as well as status epilepticus model. Up to date, three pivotal clinical studies had been completed in patients with partial seizures as an adjunctive therapy. These studies showed that retigabine doses of 600-1200 mg/day (200-400 mg three times daily) were associated with significant reduction in seizure frequency when compared with placebo. Retigabine was generally well tolerated and most commonly reported adverse events were CNS-related (i.e. dizziness and confusion) in clinical trials. This article reviewed retigabines primary mechanism of action, pharmacokinetics, and preclinical data as well as its efficacy and safety in patients with epilepsy.
Current Drug Therapy
Title: Retigabine: Could it be the Next Broad-Spectrum Antiepileptic Drug?
Volume: 5 Issue: 1
Author(s): Steve S. Chung
Affiliation:
Abstract: Retigabine is a new anticonvulsant in clinical development, which activates neuronal M-current by opening voltage-gated potassium channels (KCNQ2/3 and KCNQ3/5). Retigabine had demonstrated potent anticonvulsant activity in various animal models of epileptic seizures including partial and generalized seizure models as well as status epilepticus model. Up to date, three pivotal clinical studies had been completed in patients with partial seizures as an adjunctive therapy. These studies showed that retigabine doses of 600-1200 mg/day (200-400 mg three times daily) were associated with significant reduction in seizure frequency when compared with placebo. Retigabine was generally well tolerated and most commonly reported adverse events were CNS-related (i.e. dizziness and confusion) in clinical trials. This article reviewed retigabines primary mechanism of action, pharmacokinetics, and preclinical data as well as its efficacy and safety in patients with epilepsy.
Export Options
About this article
Cite this article as:
Chung S. Steve, Retigabine: Could it be the Next Broad-Spectrum Antiepileptic Drug?, Current Drug Therapy 2010; 5 (1) . https://dx.doi.org/10.2174/1574885511005010010
DOI https://dx.doi.org/10.2174/1574885511005010010 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Approaches Towards Designing of Isoform-Selective Inhibitors Against Class II Histone Deacetylases: The Acute Requirement for Targetted Anticancer Therapy
Current Topics in Medicinal Chemistry Neuroimaging of Non-Accidental Injury
Current Pediatric Reviews Default Mode Network Connectivity and Related White Matter Disruption in Type 2 Diabetes Mellitus Patients Concurrent with Amnestic Mild Cognitive Impairment
Current Alzheimer Research Brain Network Connectivity Mediates Education-related Cognitive Performance in Healthy Elderly Adults
Current Alzheimer Research Genetics and Molecular Biology of Tuberous Sclerosis Complex
Current Genomics Astrocytes: Implications for Neuroinflammatory Pathogenesis of Alzheimers Disease
Current Alzheimer Research Targeting Neuronal Nicotinic Receptors: a Path to New Therapies
Current Drug Targets - CNS & Neurological Disorders Adenosine and Stroke: Maximizing the Therapeutic Potential of Adenosine as a Prophylactic and Acute Neuroprotectant
Current Neuropharmacology The Role of Neuroimaging in Our Understanding of the Suicidal Brain
CNS & Neurological Disorders - Drug Targets Ion Channel Modulation as a Therapeutic Approach in Multiple Sclerosis
Current Medicinal Chemistry The Safety, Tolerability, Pharmacokinetics and Cognitive Effects of GSK239512, a Selective Histamine H<sub>3</sub> Receptor Antagonist in Patients with Mild to Moderate Alzheimer’s Disease: A Preliminary Investigation
Current Alzheimer Research Purinergic Signalling: What is Missing and Needed Next? The Use of Transgenic Mice, Crystallographic Analysis and MicroRNA
CNS & Neurological Disorders - Drug Targets Bridging Over the Troubled Heterogeneity of SPG-Related Pathologies: Mechanisms Unite What Genetics Divide
Current Molecular Medicine Autoimmune Diabetes Mellitus: The Importance of Autoantibodies for Disease Prediction and Diagnostic Support
Current Immunology Reviews (Discontinued) Receptor to Glutamate NMDA-Type: The Functional Diversity of the NR1 Isoforms and Pharmacological Properties
Current Pharmaceutical Design Sub-Chronic Exposure of Non-Observable Adverse Effect Dose of Terbufos Sulfone: Neuroinflammation in Diabetic and Non-Diabetic Rats
CNS & Neurological Disorders - Drug Targets Concurrent Estimation of Gabapentin and Nortriptyline Hydrochloride in their Combined Dosage Form Using OPA-β-Mercaptoethanol Derivatization by Spectrophotometric and Spectrofluorimetric Methods
Current Pharmaceutical Analysis Phenomenology and Neurobiology of Childhood Onset Schizophrenia
Current Psychiatry Reviews Coumarin-1,2,3-triazole Hybrid Molecules: An Emerging Scaffold for Combating Drug Resistance
Current Topics in Medicinal Chemistry Syncope: Review of Monitoring Modalities
Current Cardiology Reviews